NCT03976115已完成1 期
A Randomized, Double-Blind, Dose-escalating, Placebo Controlled, Phase I Study to Evaluate the Safety and Pharmacokinetics and Pharmacodynamics of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- Adverse Events(AEs) and Serious Adverse Events （SAEs）
研究概览
简要总结
This is a randomized, double-blind, dose-escalating, placebo controlled, Phase I study to evaluate the safety, pharmacokinetics and pharmacodynamics of DDO-3055 in healthy volunteers and patients with chronic kidney disease.
48 healthy volunteers will be enrolled in Part A, and 18 patients with chronic kidney disease will be enrolled in Part B.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers:
- •Male or female volunteers aged 18 to 45 years of age inclusive ; Hemoglobin is 120 to 160 g/L; In good health, at the discretion of the investigator, as determined by: medical history, physical examination, vital sign assessment, 12-lead ECG, clinical laboratory evaluations.
- •Patients with chronic kidney disease : Male or female patients with chronic kidney disease who are 18 to 45 years of age inclusive; Hemoglobin is ≤100 g/L; 30mL/min/1.73m2 ≤ eGFR ≤ 60mL/min/1.73m2（according to CKD-EPI formula）;
- •Body weight is ≥ 50kg, and 19kg/m2 ≤ body mass index<26kg/m2 .
- •Normal iron reserves (serum iron >61 g/dL and serum ferritin normal >30ng/mL).
- •Signed informed consent.
排除标准
- •Healthy volunteers:
- •The serum creatinine exceeded the upper limit of normal value in the screening period.
- •Healthy volunteers and patients with chronic kidney disease:
- •Allergic to the study drug or any of its ingredients.
- •Treating or treated with erythropoiesis stimulating agents for 1 month before screening.
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma-glutamyl transferase (GGT) or total bilirubin above 1.5 times normal upper limit (ULN) in the screening period.
- •Have a history of blood donation or blood transfusion within 3 months.
- •Vein blood collection is difficult or physical condition can not afford blood collection.
- •Hepatitis b surface antigen (HBsAg), hepatitis c antibody (HCVAb), syphilis antibody, or human immunodeficiency virus (HIV) antibody test is positive in the screening period.
- •Smoking 5 cigarettes per day on average within 3 months; or the average daily intake of alcohol within one week is more than 15g (15g alcohol is equivalent to 450mL beer or 150mL wine or 50mL low-alcohol liquor) or 2 days before taking the study drug and during the study period, tobacco, alcohol and caffeinated food or beverage are not prohibited, or those with special dietary requirements cannot comply with the unified diet.
- •Those who have participated in clinical trials of any drug or medical device within 3 months prior to screening, or those who have participated in the drug trial within 5 half-lives prior to screening; any health product (within 1 week prior to administration), over-the-counter drug (2 weeks prior to administration) or prescription drug (1 month prior to administration) that affects the absorption, distribution, metabolism or excretion of the tested drug.
- •With a history of drug abuse or positive screening/baseline test for substance abuse and drug urinalysis.
- •During the study period and within 30 days after administration, men who are unwilling to take contraceptive measures and promise not to donate sperm are not allowed to participate in the study. Childbearing women who did not use contraception at least 14 days before administration; men and women who did not agree to use physical contraception during the study period.
- •Women with serum HCG ≥ 5 mIU/mL or nursing in the screening period or baseline
- •Any physical or mental illness or condition that may increase the risk of the study, affect the subject's compliance with the protocol, or affect the subject's ability to complete the study, as determined by the study physician.
研究组 & 干预措施
1. healthy volunteers
Experimental
3x single dose of DDO-3055 and placebo
干预措施: DDO-3055 (Drug)
1. healthy volunteers
Experimental
3x single dose of DDO-3055 and placebo
干预措施: Placebos (Drug)
2. Patients with chronic kidney disease
Experimental
3x single dose of DDO-3055 and placebo
干预措施: DDO-3055 (Drug)
2. Patients with chronic kidney disease
Experimental
3x single dose of DDO-3055 and placebo
干预措施: Placebos (Drug)
结局指标
主要结局
Adverse Events(AEs) and Serious Adverse Events （SAEs）
时间窗: from informed consent form signature to the end of the study (up to 14 days)
Incidence of AEs and SAEs, incidence of Treatment-Emergent Adverse Events
次要结局
- Maximum observed serum concentration (Cmax) of DDO-3055(Pre-dose to 72 hours after dose administration)
- Changes in reticulocyte count relative to baseline(up to 14 days)
- Time to maximum observed serum concentration (tmax) of DDO-3055(Pre-dose to 72 hours after dose administration)
- Time to elimination half-life (t1/2) of DDO-3055(Pre-dose to 72 hours after dose administration)
- Apparent volume of distribution after non-intravenous administration (V/F) of DDO-3055(Pre-dose to 72 hours after dose administration)
- Renal clearance of the drug from plasma (CLR) of DDO-3055(Pre-dose to 72 hours after dose administration)
- Changes in red blood cell count relative to baseline(up to 14 days)
- Apparent total clearance of the drug from plasma after oral administration (CL/F) of DDO-3055(Pre-dose to 72 hours after dose administration)
- Area under the plasma concentration versus time curve (AUC) of DDO-3055(Pre-dose to 72 hours after dose administration)
- Changes in hemoglobin relative to baseline(up to 14 days)
- Changes in endogenous erythropoietin relative to baseline(up to 14 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult VolunteersHealthy VolunteersNCT02777151Regeneron Pharmaceuticals24
已完成
1 期
Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19SARS-CoV-2NCT04592549Resilience Government Services, Inc.48
已完成
1 期
A Phase I Study of GZR18 Injection in Obese/Overweight SubjectsOverweight and ObesityNCT06548945Gan and Lee Pharmaceuticals, USA16
已完成
1 期
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy SubjectsHealthy SubjectsNCT04788017Shanghai Ark Biopharmaceutical Co., Ltd.24
已完成
1 期
Safety and Tolerability Study of ZEP-3 Cream (0.1% and 1.0%), Administered Topically In Healthy VolunteersHealthyNCT01863160Shulov Innovate for Science Ltd. 201222